Andrew Evans
About Andrew Evans
Andrew Evans is the Senior Director of Cross-Portfolio Strategic Integration, Research & Early Development at Bristol Myers Squibb, with a background in marine science and extensive experience in drug development operations.
Current Role at Bristol Myers Squibb
Andrew Evans serves as the Senior Director of Cross-Portfolio Strategic Integration, Research & Early Development at Bristol Myers Squibb. Based in Princeton, New Jersey, he leads a cross-functional team to integrate strategic initiatives across multiple portfolios in early drug development. He focuses on improving collaboration between research and development teams, ensuring the seamless integration of strategic projects within the organization.
Previous Roles at Bristol Myers Squibb
Before his current role, Andrew Evans held several key positions at Bristol Myers Squibb. He was the Director of Global Drug Development Operations from 2020 to 2021 and the Associate Director of Global Drug Development Operations from 2019 to 2020. Previously, he served as the Associate Director of the International Immuno-Oncology Network (II-ON) Research Liaison for two years starting in 2017. Earlier roles include Strategic Collaborations Manager and R&D Strategy and Operations MBA Intern in 2017.
Academic and Early Career Background
Andrew Evans has a robust academic and early career background in both marine science and drug development. He completed his Ph.D. in Marine Science from The University of Texas at Austin in 2008 and a B.S. in Marine Science from Long Island University, Southampton Campus. His academic roles included being an Assistant Professor and Principal Investigator at the University of Southern Mississippi from 2012 to 2016. Before that, he worked as a RefSeq Biologist at ComputerCraft and a Postdoctoral Fellow at various institutes including the National Institute of Child Health and Human Development, NIH.
Notable Achievements and Contributions
Throughout his career, Andrew Evans has made significant contributions to both academia and industry. He played a key role in the successful launch of a new drug development program at Bristol Myers Squibb and contributed to the development of a novel immuno-oncology therapy that advanced to clinical trials. His academic achievements include authoring several peer-reviewed publications and receiving a prestigious NSF fellowship. He has also presented research findings at numerous international conferences.
Educational Background
Andrew Evans holds an MBA from Rutgers Business School, completed in 2018, and a Ph.D. in Marine Science from The University of Texas at Austin, obtained in 2008. He also holds a B.S. in Marine Science from Long Island University, Southampton Campus. His educational background has equipped him with a diverse skill set, allowing him to excel in both scientific research and business strategy.